Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT

Bioventus Inc. (NASDAQ:BVS) is one of the best medical device stocks to buy according to analystsOn August 7, Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Bioventus Inc. (NASDAQ:BVS) and set a price target of $15.00.

Tempus AI (TEM) Expands Precision Medicine Capabilities with Deep 6 AI Acquisition

A doctor repairing a foot and ankle injury using the latest sports medicine techniques.

The analyst gave the rating after Bioventus Inc. (NASDAQ:BVS) reported its fiscal Q2 results on August 6, with reported revenue of $147.7 million declining 2.4% and organic revenue advancing 6.2%.

Diluted earnings per share for Q2 was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period.

Bioventus Inc. (NASDAQ:BVS) also reported cash from operations of $25.9 million and non-GAAP earnings of $0.21 per share.

Bioventus Inc. (NASDAQ:BVS) is a medical technology company that develops and commercializes proprietary orthobiologic products to treat musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP.

While we acknowledge the potential of BVS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BVS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.